Compare Stocks: BOLT, MGX, SGMO, and BRNS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$6.27	$3.82	$3.10 ▼ $7.78	$12.10M	1	666,028 shs	12.78 million shs
BRNS Barinthus Biotherapeutics	$0.74	$0.72	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MGX Metagenomi	$0.81 -1.3%	$1.08	$0.77 ▼ $2.94	$30.43M	0.69	163,700 shs	76,731 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	+56.75%	+75.14%	+57.93%	+4.50%
BRNS Barinthus Biotherapeutics	0.00%	0.00%	0.00%	+23.14%	-44.35%
MGX Metagenomi	0.00%	+2.76%	-29.95%	-33.42%	-72.12%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-88.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLT Bolt Biotherapeutics	$6.27	$3.82	$3.10 ▼ $7.78	$12.10M	1	666,028 shs	12.78 million shs
BRNS Barinthus Biotherapeutics	$0.74	$0.72	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
MGX Metagenomi	$0.81 -1.3%	$1.08	$0.77 ▼ $2.94	$30.43M	0.69	163,700 shs	76,731 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLT Bolt Biotherapeutics	0.00%	+56.75%	+75.14%	+57.93%	+4.50%
BRNS Barinthus Biotherapeutics	0.00%	0.00%	0.00%	+23.14%	-44.35%
MGX Metagenomi	0.00%	+2.76%	-29.95%	-33.42%	-72.12%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	0.00%	-88.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLT Bolt Biotherapeutics	2.25	Hold	$14.50	131.26% Upside
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.47% Upside
MGX Metagenomi	2.33	Hold	$6.00	644.79% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside

Current Analyst Ratings Breakdown

Latest BOLT, MGX, SGMO, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	BOLT Bolt Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/22/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/9/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$7.00

(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLT Bolt Biotherapeutics	$7.70M	1.57	N/A	N/A	$13.81 per share	0.45
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
MGX Metagenomi	$25.21M	1.21	N/A	N/A	$4.22 per share	0.19
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLT Bolt Biotherapeutics	-$33.38M	-$16.44	N/A	N/A	N/A	-611.47%	-126.23%	-54.70%	11/11/2026 (Estimated)
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	11/10/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A

Latest BOLT, MGX, SGMO, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	BOLT Bolt Biotherapeutics	-$3.6850	N/A	N/A	N/A	$0.43 million	N/A
11/10/2026	Q3 2026	MGX Metagenomi	-$0.6395	N/A	N/A	N/A	$2.58 million	N/A
11/6/2026	Q3 2026	BRNS Barinthus Biotherapeutics	-$0.27	N/A	N/A	N/A	$0.22 million	N/A
8/11/2026	Q2 2026	BOLT Bolt Biotherapeutics	-$3.39	-$4.57	-$1.18	-$4.57	$0.50 million	$0.01 million
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLT Bolt Biotherapeutics	$0.36	5.74%	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLT Bolt Biotherapeutics	1.47	2.61	2.61
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
MGX Metagenomi	N/A	4.50	4.50
SGMO Sangamo Therapeutics	N/A	0.84	0.84

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLT Bolt Biotherapeutics	86.70%
BRNS Barinthus Biotherapeutics	25.20%
MGX Metagenomi	N/A
SGMO Sangamo Therapeutics	56.92%

Insider Ownership

Company	Insider Ownership
BOLT Bolt Biotherapeutics	9.40%
BRNS Barinthus Biotherapeutics	8.50%
MGX Metagenomi	12.50%
SGMO Sangamo Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLT Bolt Biotherapeutics	23	1.93 million	1.75 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
MGX Metagenomi	113	37.78 million	33.06 million	N/A
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable

BOLT, MGX, SGMO, and BRNS Headlines

Recent News About These Companies

Sangamo Therapeutics, Inc. Launches Auction Process for Clinical-Stage St-503 Program for Chronic Neuropathic Pain

October 13, 2026 | marketscreener.comM

Sangamo Therapeutics Launches Auction Process for Clinical-Stage Chronic Neuropathic Pain Program

October 13, 2026 | globenewswire.com

Sangamo Therapeutics Completes Fabry Gene Therapy Asset Sale

September 21, 2026 | tipranks.com

Sangamo Therapeutics stock falls after Nasdaq delisting to OTC market

September 19, 2026 | ad-hoc-news.deA

Sangamo Therapeutics Advances Bankruptcy Asset Sale Process

July 20, 2026 | tipranks.com

Sangamo Therapeutics Inc SGMO

July 7, 2026 | morningstar.comM

Sangamo Therapeutics Enters Into Asset Sale Agreements with Lilly and Astellas

June 24, 2026 | markets.businessinsider.com

Sangamo falls after Chapter 11 bankruptcy filing; Eli Lilly and Astellas to acquire key assets

June 24, 2026 | seekingalpha.com

Sangamo Therapeutics files for Chapter 11 bankruptcy

June 24, 2026 | msn.com

Sangamo Therapeutics Initiates Chapter 11 and Asset Sales

June 23, 2026 | tipranks.com

Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders

June 8, 2026 | globenewswire.com

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2026 Earnings Call Transcript

May 16, 2026 | insidermonkey.com

Sangamo Therapeutics Inc (SGMO) Q1 2026 Earnings Call Highlights: Progress Amidst Financial ...

May 16, 2026 | finance.yahoo.com

Sangamo Therapeutics Reports No Unregistered Equity Sales or Share Repurchases for the Period

May 16, 2026 | tipranks.com

Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript

May 14, 2026 | seekingalpha.com

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

May 14, 2026 | zacks.com

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 14, 2026 | globenewswire.com

Sangamo Therapeutics Announces First Quarter 2026 Earnings Call

May 11, 2026 | markets.businessinsider.com

Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

May 5, 2026 | finanznachrichten.de

Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)

April 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT, MGX, SGMO, and BRNS Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

$6.27 0.00 (0.00%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$6.86 +0.59 (+9.33%)

As of 10/23/2026 07:59 PM Eastern

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 10/23/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Metagenomi NASDAQ:MGX

$0.81 -0.01 (-1.30%)

Closing price 10/23/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.01 (+1.29%)

As of 10/23/2026 07:30 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 10/23/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLT, MGX, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLT, MGX, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLT, MGX, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT, MGX, SGMO, and BRNS Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Barinthus Biotherapeutics NASDAQ:BRNS

Metagenomi NASDAQ:MGX

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLT, MGX, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLT, MGX, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLT, MGX, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BOLT, MGX, SGMO, and BRNS Company Descriptions

Bolt Biotherapeutics NASDAQ:BOLT

Barinthus Biotherapeutics NASDAQ:BRNS

Metagenomi NASDAQ:MGX

Sangamo Therapeutics NASDAQ:SGMO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools